Amplia Therapeutics Reports Positive Interim Results in Cancer Trial
Company Announcements

Amplia Therapeutics Reports Positive Interim Results in Cancer Trial

Amplia Therapeutics Ltd. (AU:ATX) has released an update.

Amplia Therapeutics has reported promising interim results from its ACCENT trial, testing the drug narmafotinib in combination with chemotherapy for advanced pancreatic cancer. Six patients showed confirmed partial responses with significant tumor reduction, and the trial’s median duration is outperforming similar studies. Recruitment for the final cohort is underway, aiming to further assess the drug’s efficacy.

For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskAmplia Therapeutics Announces Major Securities Offer
TipRanks Australian Auto-Generated NewsdeskAmplia Therapeutics Announces New Securities Issuance
TipRanks Australian Auto-Generated NewsdeskAmplia Therapeutics Announces New Share and Option Offers
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App